Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01249027 · ClinicalTrials.gov registry record
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 2,605
- Enrollment target
NCT01249027: Completed study, sponsored by Abbott Medical Devices.
NCT01249027 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,605 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01249027 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 2,605 participants
- Enrollment target
Study Summary
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use * Evaluate patient compliance to dual antiplatelet therapy (DAPT)
Primary Outcome
Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery). Myocardial Infarc
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,605 participants |
| Start Date | 2010-11 |
| Est. Completion | 2017-01 |
What the finished NCT01249027 record still lists
NCT01249027 is an observational study that tracks outcomes without assigning an intervention. Its 2,605 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) is the first listed.
NCT01249027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01249027 about?
NCT01249027 is a clinical study titled "XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study". This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial...
What is the current status of trial NCT01249027?
This trial is currently completed. The enrollment target is 2,605 participants. The study started on 2010-11. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01249027?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) (DEVICE).
Who is sponsoring clinical trial NCT01249027?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia